ECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logo
  • Home
  • Contact
✕

2023

  • Home
  • 2023
July 19, 2023
July 19, 2023
Categories
  • Editorials

7 Ways Advocates Have Enhanced ECOG-ACRIN’s Cancer Research Program

ECOG-ACRIN’s cancer research advocates recently reflected on their committee’s key accomplishments
Do you like it?
0 Read more
July 19, 2023
July 19, 2023
Categories
  • New Trials

Now Enrolling: The DIRECT study is testing how well FDG-PET/CT imaging can predict if treatment is working prior to surgery for patients with HER2-positive breast cancer

This study is for patients who have untreated, early-stage HER2-positive breast cancer
Do you like it?
0 Read more
July 19, 2023
July 19, 2023
Categories
  • New Trials

Now Enrolling: ComboMATCH treatment trial E4 is testing a new option for patients with advanced solid tumors that progress despite taxane chemotherapy

This study is for patients with solid tumors that are progressing after treatment with taxane therapies
Do you like it?
0 Read more
July 19, 2023
July 19, 2023
Categories
  • Ongoing Trials

A closer look at ECOG-ACRIN’s men’s cancer trials

These trials are exploring new treatment approaches for adults with prostate or penile cancer
Do you like it?
0 Read more
1234
Next page

Office of Communications
1818 Market Street, Suite 3000
Philadelphia, PA 19103
Phone: 215.789.3631
www.ecog-acrin.org

Contact us with any questions

© 2012-2022 ECOG-ACRIN Cancer Research Group. All Rights Reserved. Designed by Create & Associates, Inc